Renal denervation as third option for the treatment of high blood pressure

The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH) published their guidelines and declared renal denervation (RDN) as third therapy option to treat hypertension.



What is renal denervation (RDN) with ultrasound?

- One-off, safe, minimally invasive treatment that has been proven to reduce high blood pressure.²⁻⁵
- Rapid recovery allows a smooth return to daily routine.
- Provides 24-hour blood pressure reductions. 2-5

More information at: www.recormedical.eu



Referring health care professional:


Contact information center			Contact details
al. Journal of Hypertension 2023, 41:1874-2017; 5 ; 4. Azizi M. et al. Lancet. 2021 Jun 26;397(1029	-	, , , ,	,

Indications for Use: The Paradise Catheter is indicated for percutaneous renal denervation. For further information on indications, contraindications, warnings, precautions, adverse events and risks, please refer to the full instructions for use.

© 2024 Recor Medical, Inc. All rights reserved. MKT-0205 EMEA/ 04-2024 RECOR MEDICAL / OTSUKA MEDICAL DEVICES EUROPE GMBH, Europa-Allee 52, 60207 Frankfurt am Main, Germany

Screening form for renal denervation (RDN)

PATIENT



EXCLUSION CRITERIA (no candidate)

- Known forms of secondary hypertension listed below*
- O Pregnancy
- 🔿 Under 18 years

ADDITIONAL RISK FACTORS (optional)

- O Prior stroke
- 🔘 Transient Ischemic Attack
- O Prior Myocardial Infarction
- 🔘 Coronary Artery Disease
- 🔘 Heart Failure
- O Atrial Fibrillation
- O Smoking
- Diabetes mellitus
- 🔘 Peripheral Vascular Disease

HTN related hospitalizations (admissions) in last 12 months

Emergency room visits related to HTN in the last 12 months